<p>(A) All siRNA transfections were performed with 12.5 nM siRNAs directed against p53 mRNA (p53 siRNAs) or non-targeting siRNAs (NT) and DharmaFECT4® transfection reagent used as a control (c). To check siRNA transfection efficiency, Western Blots were performed at 48 h using p53 or GAPDH (loading control) antibody. (B) The knockdown of p53 expression by siRNAs relative to GAPDH was quantified using the Bio1D software (mean values ± SEM of three experiments *p<0.05) (C) DNA was isolated from untransfected cells or transfected with NT siRNAs or with p53 siRNAs. Cells were also permeabilized with 0.1% Triton X100 and pretreated for 1 h with 1 µg/ml phosphoSer<sup>15</sup>p53 antibody (phosphoSer<sup>15</sup>Ab). Cells were then treated for 0...
<p>A) HBL-100 cells express wild type p53, while HS578T cells express mutant p53. The levels of PAPP...
<p><b>Copyright information:</b></p><p>Taken from "Cancer-derived p53 mutants suppress p53-target ge...
Background and aims. siRNAs represent an encouraging novel alternative in cancer therapy as a result...
<p>(A) All siRNA transfections were performed or not (control, C) with 12.5 nM siRNAs directed again...
The roles and actions of the tumor suppressor protein p53 have been extensively studied with regard ...
<p>A. U2OS cells were transfected with NIR-specific siRNA or control siRNA respectively. At 72 hrs p...
<p>(A) RT-PCR analysis for p53 and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) in C2C12 cells t...
<p>(A) Real time PCR examination of MC3T3-E1 cells in which the p53 gene function was silenced by si...
<p>318–1 cells were transfected with different concentrations of control or p53 siRNA encapsulated i...
<p>(A) 10 nM of newly designed siR-tp53 successfully knockdowned the expression of p53 protein from ...
The roles and actions of the tumor suppressor protein p53 have been extensively studied with regard ...
<p>Cells were either not transfected or transfected with 100 nM p53 siRNA and then treated with 3 µM...
<p>(<b>A</b>) Relative expression levels of p53 and FHL2-1a in HepG2 cells treated with p53-siRNA wi...
<p>Down-regulation of p53 expression by p53 RNAi during ER stress. (A) MCF-7 cells were cotransfect ...
<p>(A) Immunoblotting in OVMANA cells treated with DS-7423 at the indicated doses. Phosphorylation l...
<p>A) HBL-100 cells express wild type p53, while HS578T cells express mutant p53. The levels of PAPP...
<p><b>Copyright information:</b></p><p>Taken from "Cancer-derived p53 mutants suppress p53-target ge...
Background and aims. siRNAs represent an encouraging novel alternative in cancer therapy as a result...
<p>(A) All siRNA transfections were performed or not (control, C) with 12.5 nM siRNAs directed again...
The roles and actions of the tumor suppressor protein p53 have been extensively studied with regard ...
<p>A. U2OS cells were transfected with NIR-specific siRNA or control siRNA respectively. At 72 hrs p...
<p>(A) RT-PCR analysis for p53 and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) in C2C12 cells t...
<p>(A) Real time PCR examination of MC3T3-E1 cells in which the p53 gene function was silenced by si...
<p>318–1 cells were transfected with different concentrations of control or p53 siRNA encapsulated i...
<p>(A) 10 nM of newly designed siR-tp53 successfully knockdowned the expression of p53 protein from ...
The roles and actions of the tumor suppressor protein p53 have been extensively studied with regard ...
<p>Cells were either not transfected or transfected with 100 nM p53 siRNA and then treated with 3 µM...
<p>(<b>A</b>) Relative expression levels of p53 and FHL2-1a in HepG2 cells treated with p53-siRNA wi...
<p>Down-regulation of p53 expression by p53 RNAi during ER stress. (A) MCF-7 cells were cotransfect ...
<p>(A) Immunoblotting in OVMANA cells treated with DS-7423 at the indicated doses. Phosphorylation l...
<p>A) HBL-100 cells express wild type p53, while HS578T cells express mutant p53. The levels of PAPP...
<p><b>Copyright information:</b></p><p>Taken from "Cancer-derived p53 mutants suppress p53-target ge...
Background and aims. siRNAs represent an encouraging novel alternative in cancer therapy as a result...